Get started

Sichuan Baili Pharmaceutical Co., Ltd. (China)

Alternate names: Baili Pharmaceutical, Sichuan Baili Pharmaceutical, Sichuan Baili Pharmaceutical Co., Ltd., Sichuan Baili Pharmaceuticals Co., Ltd.
ROR: 058bkh621
OpenAlex ID: I4405267978
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
2024 · Yuxiang Ma, Yan Huang, et al. · The Lancet Oncology · 184
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China
2025 · Yunpeng Yang, Huaqiang Zhou, et al. · The Lancet · 37
BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study.
2023 · Li Zhang, Yuxiang Ma, et al. · Journal of Clinical Oncology · 29
Abstract 2642: BL-B01D1, a novel EGFR×HER3-targeting ADC, demonstrates robust anti-tumor efficacy in preclinical evaluation
2023 · Weili Wan, Shuwen Zhao, et al. · Cancer Research · 28
Prediction of Human Pharmacokinetics and Clinical Effective Dose of SI–B001, an EGFR/HER3 Bi-specific Monoclonal Antibody
2020 · Junsheng Xue, Daming Kong, et al. · Journal of Pharmaceutical Sciences · 26
Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
2025 · Jinhui Xue, Yuxiang Ma, et al. · Clinical Cancer Research · 19
PDF
SI-B001 plus chemotherapy in patients with locally advanced or metastatic EGFR/ALK wild-type non-small cell lung cancer: A phase II, multicenter, open-label study.
2023 · Yuanyuan Zhao, Li Zhang, et al. · Journal of Clinical Oncology · 19
Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with driver genomic alterations (GA) outside of classic EGFR mutations.
2025 · Yunpeng Yang, Li Zhang, et al. · Journal of Clinical Oncology · 13
PDF
Abstract 5679: Tetra-specific antibody GNC-035: guidance and navigation control (GNC) molecule development for treatment of ROR1+ malignancies
2023 · Jahan Salar Khalili, Sa Xiao, et al. · Cancer Research · 12
Results from two phase II studies of SI-B001, an EGFR×HER3 bispecific antibody, with/without chemotherapy in patients (pts) with recurrent and metastatic head and neck squamous cell carcinoma (HNSCC).
2023 · Liqiong Xue, Kunyu Yang, et al. · Journal of Clinical Oncology · 11
Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic small cell lung cancer (SCLC).
2025 · Yan Huang, Li Zhang, et al. · Journal of Clinical Oncology · 9
GNC-038, a tetra-specific antibody, in patients with R/R non-Hodgkin lymphoma or acute lymphoblastic leukemia: A phase 1 study design and rationale.
2023 · Jianxiang Wang, Junyuan Qi, et al. · Journal of Clinical Oncology · 9
Abstract 5681: Tetra-specific antibody GNC-038: guidance and navigation gontrol (GNC) molecule development for treatment of CD19+ malignancies
2023 · Jahan Salar Khalili, Sa Xiao, et al. · Cancer Research · 8
Abstract 5680: Tetra-specific antibody GNC-039: guidance and navigation control (GNC) molecule development for treatment of EGFRvIII+ malignancies
2023 · Jahan Salar Khalili, Sa Xiao, et al. · Cancer Research · 8
SI-B003 (PD-1/CTLA-4) in patients with advanced solid tumors: A phase I study.
2023 · Yakun Wang, Yongsheng Li, et al. · Journal of Clinical Oncology · 7
PDF
Abstract 2643: BL-M07D1, a novel HER2-targeting ADC, demonstrates potent anti-tumor efficacy in preclinical pharmacodynamic models
2023 · Weili Wan, Shuwen Zhao, et al. · Cancer Research · 7
Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study
2026 · Yuanyuan Zhao, Hongyun Zhao, et al. · Journal of Clinical Oncology · 6
Abstract 6309: Anti-tumor efficacy of SI-B001, a novel EGFR × HER3 bispecific antibody, against EGFR-driven epithelial tumors alone or in combination with paclitaxel and carboplatin
2023 · Blair Renshaw, Jahan Salar Khalili, et al. · Cancer Research · 6
New Insights: MicroRNA Function in CNS Development and Psychiatric Diseases
2018 · Qian Liu, Lu Zhang, et al. · Current Pharmacology Reports · 6
Izalontamab brengitecan (iza-bren) versus physician’s choice of chemotherapy in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC): A randomized phase III study.
2026 · Jiong Wu, Jian Zhang, et al. · Journal of Clinical Oncology · 4
Izalontamab brengitecan (iza-bren) versus chemotherapy in patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC): A multicenter, randomized, open-label, phase III study.
2026 · Zhihao Lu, Zhangzhou Huang, et al. · Journal of Clinical Oncology · 4
Research Progress on Nano-Drug Delivery Systems for Photothermal Cancer Therapy
2026 · Tao Li, Dan Xiao, et al. · International Journal of Nanomedicine · 4
Safety and antitumor activity of the first-in-class EGFR–HER3 bispecific antibody–drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase Ib study
2026 · J. Zhang, Y. Meng, et al. · Annals of Oncology · 2
PDF
Phase I study of BL-M05D1, a novel Claudin18.2-directed antibody-drug conjugate (ADC), in patients with locally advanced or metastatic Claudin18.2–expressing solid tumors.
2026 · Siyuan Cheng, Xinyi Yang, et al. · Journal of Clinical Oncology · 2
Phase I study of BL-M14D1, a novel DLL3-directed antibody-drug conjugate (ADC), in patients with locally advanced or metastatic small-cell lung cancer (SCLC), neuroendocrine carcinoma (NEC), and other solid tumors.
2026 · Wei Li, Yuping Sun, et al. · Journal of Clinical Oncology · 2
PDF
Works count: 39
Citation count: 1,589
Year
Topic
Type